Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia, Myeloid, Acute 6Leukemia 6Burkitt Lymphoma 5Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Leukemia, Prolymphocytic 3Myeloproliferative Disorders 2Leukemia, Plasma Cell 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Congenital Abnormalities 2Tumor Lysis Syndrome 1Sarcoma, Alveolar Soft Part 1Recurrence 1Primary Myelofibrosis 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid 1

Interventions

Dexamethasone 6fludarabine 5Whole-Body Irradiation 5Mycophenolic Acid 5Melphalan 5Lenalidomide 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Tacrolimus 3Calcium Dobesilate 3Bortezomib 3dexamethasone acetate 2dexamethasone 21-phosphate 2daratumumab 2auricularum 2Stem Cell Transplantation 2Sirolimus 2Antilymphocyte Serum 2Allopurinol 2pomalidomide 1plerixafor 1pegylated granulocyte colony-stimulating factor 1liposomal doxorubicin 1ixazomib 1isatuximab 1ferric pyrophosphate 1elotuzumab 1carmustine, poliferprosan 20 drug combination 1carfilzomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, Plasma Cell × Allopurinol × Clear all
NCT05805605 2025-07-01

Allo HSCT Using RIC and PTCy for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Recruiting
56 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Leukemia, Myeloid, Leukemia, Plasma Cell, Lymphoma, Follicular, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Lymphoma, B-Cell, Marginal Zone, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT02661035 2023-09-21

Allo HSCT Using RIC for Hematological Diseases

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
156 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hematologic Diseases, Leukemia, Plasma Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡